uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Expression of somatostatin receptor subtypes 1-5 in malignant endocrine pancreatic tumors
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
Article in journal (Refereed) Submitted
URN: urn:nbn:se:uu:diva-90040OAI: oai:DiVA.org:uu-90040DiVA: diva2:162079
Available from: 2002-10-24 Created: 2002-10-24Bibliographically approved
In thesis
1. Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects
Open this publication in new window or tab >>Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects
2002 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

We treated 16 patients with somatostatin analogs combined with α-interferon and achieved a biochemical and/or radiological response in 56% (median duration 22 months). We consider this treatment a good alternative for patients who fail during chemotherapy or who do not want to/cannot receive cytotoxic drugs.

Thirty-six patients with neuroendocrine tumors were treated with cisplatin combined with etoposide. Of 14 patients with evaluable EPTs, 50% responded radiologically and/or biochemically (median duration 9 months). We consider this treatment useful as first-line medical treatment in aggressive EPTs or in patients failing prior chemotherapy.

Twenty-eight tumor tissues from EPTs were examined with immunohistochemistry regarding expression of somatostatin receptors (ssts) 1 to 5 on tumor cells and in intratumoral vessels. We found that sst2 and sst4 were highly expressed on tumor cells and in vessels. However, sst3 and sst5 were lacking in half of the tumor tissues and in most of the vessels. Because of the variability in sst expression, we recommend analysis of each individual’s receptor expression before starting treatment.

Endocrine pancreatic tumors (EPTs) are rare with an incidence of 4 per million inhabitants. In the majority of cases they grow slowly, but there are exceptions with very rapidly progressing malignant carcinomas. First-line medical treatment is streptozotocin combined with 5-fluorouracil.

We examined 38 tumor samples regarding expression of tyrosine kinase receptors platelet-derived growth factor receptors (PDGFRs), c-kit and epidermal growth factor receptor (EGFR). We found that the receptors were expressed in more than half of the tumor tissues. Further studies will reveal if tyrosin kinase antagonists can be part of the future treatment arsenal.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2002. 71 p.
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 0282-7476 ; 1191
Medical sciences, pancreatic tumors, somatostatin analogs, cisplatin, etoposide, somatostatin receptors, immunohistochemistry, tyrosine kinase receptors, platelet-derived growth factors receptors (PDGFRs), c-kit, epidermal growth factor receptor (EGFR), MEDICIN OCH VÅRD, alfa-interferon
National Category
Medical and Health Sciences
Research subject
urn:nbn:se:uu:diva-2709 (URN)91-554-5424-0 (ISBN)
Public defence
2002-11-16, Aulan, ingång 50, Akademiska sjukhuset, Uppsala, 09:15
Available from: 2002-10-24 Created: 2002-10-24Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 34 hits
ReferencesLink to record
Permanent link

Direct link